MA5-15134

antibody from Invitrogen Antibodies

Targeting: MAPK3 ERK1, p44erk1, p44mapk, PRKM3

Provider product page for MA5-15134

Western blot

Immunoprecipitation

Antibody data

Antibody Data
Antigen structure
References [0]
Comments [0]
Validations
Western blot [2]
Immunocytochemistry [3]
Immunohistochemistry [1]
Flow cytometry [1]
Other assay [4]

Submit

Product number: MA5-15134 - Provider product page
Provider: Invitrogen Antibodies
Product name: ERK1/ERK2 Monoclonal Antibody (K.913.4)
Antibody type: Monoclonal
Antigen: Synthetic peptide
Description: It is not recommended to aliquot this antibody. This antibody is not cross-reactive with JNK/SAPK or p38 MAP kinase.
Reactivity: Human, Mouse, Rat, Bovine, Canine, Drosophila, Hamster, Porcine, Zebrafish
Host: Rabbit
Isotype: IgG
Antibody clone number: K.913.4
Vial size: 200 µL
Concentration: 84 µg/mL
Storage: -20°C

MAPK3 protein structure - MA5-15134 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis was performed on whole cell extracts (30 µg lysate) of HeLa (Lane 1), H1975 (Lane 2), HCT 116 (Lane 3), HT-29 (Lane 4), A-431 (Lane 5), A549 (Lane 6), MDA-MB-231 (Lane 7), RSC96 (Lane 8), PC-12 (Lane 9) and NIH/3T3 (Lane 10). The blot was probed with Rabbit Anti-ERK1/ERK2 Monoclonal Antibody (Product # MA5-15134, 1:1000 dilution) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.25 µg/mL, 1:4000 dilution). Two bands at 42, 44 kDa corresponding to ERK1/ERK2 was observed across the cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockdown of ERK1/ERK2 was achieved by transfecting MCF7 cells with ERK1/ERK2 specific validated siRNAs (Silencer® select Product # s11140, s11137 and s11138). Western blot analysis (Fig a) was performed using whole cell lysates from the ERK1 knockdown cells (lane 4), ERK1/ERK2 knock down cells (lane 3), non-specific scrambled siRNA transfected cells (lane 2) and untransfected cells (lane 1). The blots were probed with Anti-ERK1/ERK2 Rabbit Monoclonal Antibody (Product # MA5-15134, 1:1000 dilution) and Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.25 µg/mL, 1:4000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig b). Loss of signal upon siRNA mediated knock down confirms that antibody is specific to ERK1/ERK2.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of ERK1/ERK2 was performed using 70% confluent log phase RSC96 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with ERK1/ERK2 Rabbit Monoclonal Antibody(K.913.4) (Product # MA5-15134) at 1:100 dilution in 0.1% BSA, incubated at 4 degree Celsius overnight and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of p44/42 MAPK (Erk1/2) in NIH/3T3 cells, treated with either U0126 (MEK1/2 Inhibitor), using a p44/42 MAPK (Erk1/2) monoclonal antibody (Product # MA5-15134) (green). Actin filaments are labeled with a fluorescent red phalloidin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of p44/42 MAPK (Erk1/2) in NIH/3T3 cells, treated with PDGF, using a p44/42 MAPK (Erk1/2) monoclonal antibody (Product # MA5-15134) (green). Actin filaments are labeled with a fluorescent red phalloidin.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 9 a ERK before (CHF) and after LVAD therapy (CHF+LVAD) as compared to non-failing ventricles (NF), left. The same comparisons in the subgroup of patients with a baseline left ventricular ejection fraction above the median value, right ( n = 10). ERK expression was determined by immunoblot (western blot) analysis and referred to a standard, respectively, whose densitometric value was set 1 by default. The value on the y -axis, therefore, reflects the percentage of each parameter's immunoblot band density in relation to this default value. AU arbitrary unit, BL-LVEF baseline left ventricular ejection fraction, CHF congestive heart failure, LVAD left ventricular assist device, NF non-failing myocardial tissue specimen. b ERK before (CHF) and after LVAD therapy (CHF+LVAD) as compared to non-failing ventricles (NF) in the subgroup of ICM patients, left ( n = 8). The same comparisons in the subgroup of patients with a duration of LVAD therapy below the median value, right ( n = 10). AU arbitrary unit, CHF congestive heart failure, ICM ischemic cardiomyopathy, LVAD left ventricular assist device, NF non-failing myocardial tissue specimen

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 11 MAPK1 expression by IF double staining 5d after seeding. CTR = cIECs cultured without growth factors - GF = cIECs cultured with growth factors a CTR contrast-phase image; b CTR FITC only; c CTR FITC+DAPI; d GF contrast-phase image; e GF FITC only; f) GF FITC+DAPI. Cells were double-stained for c-MYC and MAPK1

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 MEK1/2-RK1/2 and STAT3 play indispensable, yet distinct roles in mammary epithelial cell migration. A , both the STAT3 inhibitor S3I-201 and the MEK1/2 inhibitor U0126 blocked migration of the MCF-10A cells induced by EGF. Shown are percentage of wound healing (in 16 h) in the presence or the absence of EGF and/or the inhibitor. n = 3, ** p < 0.001; Student's t test. B , both S3I-201 and U0126 abrogated EGF-induced upregulation of CTEN expression. Data shown are obtained from samples with 8 h of treatment. C , Western blot showing the dynamic changes in the TNS3 and CTEN protein during 8 h of EGF treatment. Total and phosphorylated ERK1/2 and STAT3 were detected using specific antibodies. n = 3, * p < 0.05, ** p < 0.001; Student's t test. D , distinct binding profiles for STAT3 and ERK1/2 to the cten gene promoter at different time points of EGF treatment, graphed from the corresponding ChIP-PCR data. E , U0126 abrogated ERK1/2 phosphorylation at all time points but inhibited STAT3-Tyr705 phosphorylation only at late time points of EGF stimulation ( i.e. , 3 and 8 h). F , S3I-201 blocked STAT3-Tyr705 phosphorylation but had no effect on ERK1/2 phosphorylation. ChIP, chromatin immunoprecipitation; CTEN, C-terminal tension; EGF, epithelial growth factor; ERK1/2, extracellular signal-regulated protein kinase 1/2; MEK1/2, mitogen-activated protein kinase kinase 1/2; STAT3, signal transducer and activator of transcription 3; TNS3, tensin-3.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 The IL-6-STAT3-IL-6 feedback loop facilitates cell migration in response to continuous EGF treatment. A , IL-6 promoted EGF stimulated cell migration, whereas an anti-IL-6 antibody (alphaIL-6) significantly reduced cell migration. n = 3, * p < 0.05, Student's t test. B , IL-6 promoted STAT3-Y705 phosphorylation but had no effect on ERK1/2 phosphorylation. C , alphaIL-6 markedly reduced STAT3 phosphorylation but had no effect on ERK1/2 activation induced by EGF stimulation for 3 h. D and E , pharmacological inhibition of the EGFR, JAK, and Src kinases reduced or blocked STAT3 phosphorylation. F, relevant kinase inhibitors and anti-IL-6 antibody all decreased CTEN expression induced by EGF. G , nuclear translocation of STAT3 (STAT3-pY705) and ERK1/2 (pERK1/2) during continuous EGF stimulation. H , IL-6 transcription was regulated by ERK1/2 in the early phase ( e.g. , 10 min), but by STAT3 in the later phase ( e.g. , 3 h) of EGF stimulation. n = 3, * p < 0.05; ** p < 0.001, Student's t test. I , both S3I-201 and U0126 effectively blocked EGF-induced IL-6 expression in MCF-10A cells. EGF, epithelial growth factor; EGFR, epithelial growth factor receptor; ERK1/2, extracellular signal-regulated protein kinase 1/2; IL-6, interleukin-6; JAK, Janus kinase; STAT3, signal transducer and activator of transcription 3.